Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of ALXN1840 on biliary copper excretion in Wilson's disease measured by 64CuCl2 PET/MR
2021-000102-25Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atn-224 in Wilson disease (WD), sponsored by Aarhus University Hospital. Started Feb 2021; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2021-000102-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000102-25.